| Name | Title | Contact Details |
|---|
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.
We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.
Bioriginal Food and Science Corp. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bioreclamation is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.